IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.

NCT05975931 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2024-12-03

No results posted yet for this study

Summary

This is a retrospective non-interventional study to describe the HCRU and clinical outcomes before and after AspireSR® device implantation in subjects with drug resistant epilepsy at the Queen Elizabeth Hospital, Birmingham (QEHB).

Conditions

Sponsors & Collaborators

  • OPEN VIE Limited

    collaborator UNKNOWN
  • LivaNova

    lead INDUSTRY

Principal Investigators

  • Barbara Wysota · The Queen Elizabeth Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2024-01-30
Completion
2024-01-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05975931 on ClinicalTrials.gov